Paris, March 7 2023 – iPSirius, a leading biotechnology company focused on the development of innovative immunotherapies, announced that it has been granted its second American patent for a novel technology that enables the production of ‘off-the-shelf’ cancer vaccines from induced pluripotent stem cells (iPSCs). [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
How the MSC Market is Coming of Age in 2023
MSCs are a class of multipotent cells that are readily found in umbilical cord tissue, adipose tissue, bone marrow, dental pulp, and periosteum (a type of connective tissue that envelops bone). These cells are often called by other names as well, such as Medicinal Signaling Cells, Mesenchymal Stromal Cells, Marrow Stromal Cells, and Mesenchymal Stem Cells, despite much controversy in the field about using this term. [Read more…]
History of Cord Blood and Cord Tissue Banking
The history of cord blood and tissue banking dates back to the early 1990’s when three private cord blood banks were formed within the United States. These banks were Cord Blood Registry, Cryo-Cell, and Viacord, all of which are AABB accredited banks. Shortly thereafter, cord blood banks began forming in leading healthcare markets worldwide.
In this article:
CooperSurgical® Announces More than 11,000 Families Have Enrolled in Newborn Possibilities Program®
Program provides free cord blood and tissue processing to qualifying families in need.
TRUMBULL, Conn., Jan. 5, 2023 — CooperSurgical, a global leader in fertility and women’s health, shared that more than 11,000 families have enrolled in the Newborn Possibilities Program® through their Cord Blood Registry® (CBR®) brand. Through the Newborn Possibilities Program, CBR offers free cord blood and tissue processing and five years of storage for families with a qualifying medical need. [Read more…]
70% of Global Cord Blood Market Controlled by World’s 12 Largest Operators
For both therapeutic and financial reasons, the cord blood industry has been witnessing record levels of M&A activity in recent years, with market leaders gaining market share at the expense of smaller competitors and investors vying for buy-in opportunities. Novel pricing strategies, product cross-sells and upsells, and ingenious online and offline marketing strategies are being implemented by the industry’s market leaders. Meanwhile, new technologies to support ex vivo cord blood expansion are advancing at brisk pace, indicating a promising future for the industry.
Given the operational efficiencies associated with market consolidation, the global cord blood and tissue banking market is being consolidated by a handful of large and well capitalized market competitors. [Read more…]
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 63
- Next Page »